FT Videos & Podcasts
但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
，推荐阅读safew官方下载获取更多信息
"Cuba will defend itself with determination and firmness against any terrorist and mercenary aggression that seeks to affect its sovereignty and national stability," Díaz-Canel said on X.
Very rare Iron Age trumpet sells for more than £4k